Melissa S. Harris
Pfizer (United States)(US)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Biochemical and Molecular Research, Hepatitis C virus research, Lipoproteins and Cardiovascular Health, Enzyme Structure and Function
Most-Cited Works
- → Does tailoring matter? Meta-analytic review of tailored print health behavior change interventions.(2007)2,137 cited
- → Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms(2014)179 cited
- → Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim(2009)134 cited
- → A Short-Term, Quasi-Experimental Evaluation of D.A.R.E.'s Revised Elementary School Curriculum(2010)68 cited
- → Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors(2010)68 cited
- → Inhibitors of HCV NS5B polymerase. Part 1: Evaluation of the southern region of (2Z)-2-(benzoylamino)-3-(5-phenyl-2-furyl)acrylic acid(2005)67 cited
- → Thermodynamic and Structure Guided Design of Statin Based Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase(2008)64 cited
- → A Structural Variation for MurB: X-ray Crystal Structure of Staphylococcus aureus UDP-N-Acetylenolpyruvylglucosamine Reductase (MurB)(2001)62 cited
- → Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3R,5R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia(2007)58 cited
- → Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors(2007)55 cited